Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. (Q33750043)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10517488%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

review article

1 reference

title

Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10517488%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

main subject

chronic myeloid leukemia

0 references

leukemia

1 reference

stem cell transplantation

inferred from title

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10517488%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

Richard Szydlo

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10517488%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

author name string

J M Goldman

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10517488%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

publication date

1 October 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10517488%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

published in

Experimental Hematology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10517488%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10517488%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10517488%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

page(s)

1477-1486

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10517488%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

cites work

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Allografting for chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T-depleted donor marrow: feasibility of using busulphan alone for re-conditioning

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Comparative Outcomes of T-Cell–Depleted and Non–T-Cell–Depleted Allogeneic Bone Marrow Transplantation for Chronic Myelogenous Leukemia: Impact of Donor Lymphocyte Infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Anergic T cells as suppressor cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Possible induction of graft-versus-leukemia effect against a leukemia refractory to antileukemia response in ordinary MHC-compatible, allogeneic bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

1 reference

7 January 2021

Immunologic nonresponsiveness to tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

T cell subsets and graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Transplantation of anergic histoincompatible bone marrow allografts

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

CTLA-4 is a second receptor for the B cell activation antigen B7

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent mu

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Therapy with cultured T cells: principles revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Immune surveillance against a solid tumor fails because of immunological ignorance

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Identification of classical minor histocompatibility antigen as cell-derived peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Identification of a graft versus host disease-associated human minor histocompatibility antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Neonatal Tolerance Revisited: Turning on Newborn T Cells with Dendritic Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2899%2900096-X

7 January 2021

10.1016/S0301-472X(99)00096-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10517488%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference